In-vivo Bioequivalence Study of Ozanimod 0.92 mg Capsules of The Test Drug (WELLOSIA® 0.92 mg Caps., Nano-Alvand Pharma, Iran)

In-vivo Bioequivalence Study of Ozanimod 0.92 mg Capsules of The Test Drug (WELLOSIA® 0.92 mg Caps., Nano-Alvand Pharma, Iran) in Compared with The Reference Drug (ZEPOSIA® 0.92 mg, Celgene, USA) In Iranian Healthy Volunteers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200105046010N141

Enrollment

Registered

2025-05-09

Start date

2025-05-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This study is performed on healthy volunteers and drug concentration in plasma is determined..

Interventions

Intervention 1: Intervention group:. Intervention 2: Control group:.

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: General health(liver, heart, kidney) Body mass index(18-30) Informed consent Age(18-55)

Exclusion criteria

Exclusion criteria: Smoking history of cardiovascular disease history of liver & kidney disease Alcohol & Drug addiction Hypersensitivity to the drug Pregnancy

Design outcomes

Primary

Measure	Time frame
Drug plasma concentration. Timepoint: 1 ?2 ?3 ?4 ?6 ?8 ?10 ?12 ?24 ?48 ?72 96 , 120 h after drug administration. Method of measurement: Liquid Chromatography Mass-Mass.	—

Secondary

Measure	Time frame
Time to reach maximum plasma concentration. Timepoint: After intervention. Method of measurement: Time to reach the maximum drug concentration in plasma is recorded.;Extent of absorption. Timepoint: After intervention. Method of measurement: Calculation of area under curve of concentration -time.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJavad Shokri

Tabriz University of Medical Sciences

shokri.j@gmail.com+98 41 3661 4125

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026